Premium
Early recurrence of well‐differentiated (G1) neuroendocrine liver metastasis after curative‐intent surgery: Risk factors and outcome
Author(s) -
Xiang JunXi,
Zhang XuFeng,
Weiss Matthew,
Aldrighetti Luca,
Poultsides George A.,
Bauer Todd W.,
Fields Ryan C.,
Maithel Shishir Kumar,
Marques Hugo P.,
Pawlik Timothy M.
Publication year - 2018
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.25246
Subject(s) - medicine , hazard ratio , surgery , metastasis , confidence interval , neuroendocrine tumors , proportional hazards model , survival analysis , gastroenterology , cancer
Background The objective of the current study was to identify the risk of early vs late recurrence of well‐differentiated (G1) neuroendocrine liver metastasis (NELM) after curative‐intent resection. Methods Patients who underwent curative‐intent resection for well‐differentiated NELM were identified from a multi‐institutional database. Clinicopathological details, as well as the long‐term overall (OS) and recurrence free survival (RFS) were obtained and compared. The optimal cutoff value to differentiate early and late recurrence was determined to be 1 year based on trend curve analysis. Results Among the 548 patients undergoing curative resection for NELM, 162 patients had a well‐differentiated NELM. After a median follow‐up of 69 months, 59 (36.4%) patients had tumor recurrence; 23 (39.0%) patients recurred within 1 year (early recurrence) after surgery, while 36 (61.0%) recurred after 1 year (late recurrence). Early recurrence was associated with worse outcome vs late recurrence (5‐year OS, 72.4% vs 92.0%; P = 0.020) and no recurrence (5‐year OS, 72.4% vs 100.0%; P < 0.001). In addition, postrecurrence survival was worse within 36 months after recurrence among patients who recurred early compared with patients who recurred late (survival after recurrence at 36 months: early recurrence, 71.6% vs late recurrence, 91.4%; P = 0.047), although survival was comparable at 60 months (early recurrence, 71.6% vs late recurrence, 70.0%; P = 0.304). On multivariable analysis, nonfunctional neuroendocrine tumors (hazard ratio [HR], 4.4; 95% confidence interval [CI], 1.2‐16.7; P = 0.029) and lymph node metastasis (HR, 3.6; 95% CI, 1.1‐11.1; P = 0.028) were independent risk factors for early recurrence, whereas lymph node metastasis (HR, 3.0; 95% CI, 1.2‐7.8; P = 0.020) and R1 resection (HR, 3.9; 95% CI, 1.4‐10.5; P = 0.008) were independently associated with late recurrence. Conclusions Roughly, one‐third of patients with well‐differentiated NELM experienced a recurrence following curative‐intent surgery. Among patients who recurred, two out of five patients recurred within 1 year after surgery. Early recurrence of well‐differentiated NELM was associated with the hormone functional status and lymph node metastasis.